Analysen von Richard Vosser
| 29.03.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 29.03.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 28.03.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 24.03.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 22.03.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 14.03.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 14.03.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 11.03.22 | Roche Neutral | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 10.03.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 08.03.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 08.03.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 04.03.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 03.03.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 03.03.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 02.03.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 01.03.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 28.02.22 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 04.04.22 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 18.02.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 14.02.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 11.02.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 09.02.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 08.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 04.02.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 03.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 03.02.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 02.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.02.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 01.02.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 01.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.22 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 26.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 26.01.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 26.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 25.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 24.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 20.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 13.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 13.01.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 13.01.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 12.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 12.01.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 04.01.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 04.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 04.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 04.01.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 04.01.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 04.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 04.01.22 | GSK Neutral | JP Morgan Chase & Co. | |